Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World’s First Phase III Trial of a Generative AI-Driven Innovative Drug (IMAGE)

InSilico Medicine

Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World’s First Phase III Trial of a Generative AI-Driven Innovative Drug

Caption

Till today, Insilico has published multiple peer-reviewed papers to document the milestones of Rentosertib along the R&D journey, all the way from target identification to Phase IIa positive results. In 2024, a Nature Biotechnology publication demonstrated the AI-driven early discovery process of Rentosertib. In 2025, a Nature Medicine study reported Phase IIa results of Rentosertib, demonstrating a promising dose-dependent efficacy trend. Most recently, in 2026, a Nature Biotechnology study revealed a consistent reduction in biological age after Rentosertib dosage, across six independent biological aging clocks.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.